Eric Joseph
Stock Analyst at JP Morgan
(1.32)
# 3,458
Out of 4,884 analysts
134
Total ratings
36.05%
Success rate
-11.82%
Average return
Main Sectors:
Stocks Rated by Eric Joseph
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Overweight | $57 → $64 | $44.79 | +42.89% | 3 | Jun 3, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $3.11 | - | 5 | May 20, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $45 → $44 | $2.90 | +1,417.24% | 3 | May 9, 2025 | |
| NVAX Novavax | Maintains: Underweight | $9 → $7 | $6.80 | +2.94% | 8 | May 9, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $75 → $67 | $49.07 | +36.54% | 10 | May 7, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.36 | - | 4 | Apr 25, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Neutral | n/a | $1.26 | - | 4 | Feb 10, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $31 → $30 | $12.73 | +135.66% | 7 | Jan 29, 2025 | |
| IGMS IGM Biosciences | Upgrades: Neutral | n/a | $1.36 | - | 8 | Jan 13, 2025 | |
| VIR Vir Biotechnology | Maintains: Neutral | $10 → $14 | $5.41 | +158.78% | 5 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $63 → $71 | $37.87 | +87.48% | 6 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $43 | $36.72 | +17.10% | 4 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $11.37 | +234.21% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $1.43 | +1,508.39% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $6.95 | +144.60% | 2 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $3.63 | +478.51% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $48 | $20.01 | +139.88% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $7.89 | +26.74% | 4 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.06 | - | 4 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $15 | $1.66 | +803.61% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6 | $1.48 | +305.41% | 4 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $11 → $10 | $5.27 | +89.75% | 2 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $11 | $4.87 | +125.87% | 2 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $41 | $51.77 | -20.80% | 2 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $300 → $100 | $9.69 | +931.99% | 1 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 → $5 | $0.56 | +800.74% | 2 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.74 | - | 6 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $11 | $4.32 | +154.63% | 6 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $8.36 | - | 2 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 | $4.39 | +2,633.49% | 2 | Feb 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $750 → $300 | $7.84 | +3,726.53% | 2 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.20 | - | 2 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $11.28 | +343.26% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $24 → $9 | $2.37 | +279.75% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.62 | - | 4 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $2.58 | +1,527.91% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 → $13 | $0.77 | +1,597.13% | 2 | Jan 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $11 | $0.53 | +1,987.68% | 3 | Nov 14, 2018 |
Kymera Therapeutics
Jun 3, 2025
Maintains: Overweight
Price Target: $57 → $64
Current: $44.79
Upside: +42.89%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $3.11
Upside: -
Rocket Pharmaceuticals
May 9, 2025
Maintains: Overweight
Price Target: $45 → $44
Current: $2.90
Upside: +1,417.24%
Novavax
May 9, 2025
Maintains: Underweight
Price Target: $9 → $7
Current: $6.80
Upside: +2.94%
PTC Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $75 → $67
Current: $49.07
Upside: +36.54%
OPKO Health
Apr 25, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.36
Upside: -
Pliant Therapeutics
Feb 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.26
Upside: -
Nurix Therapeutics
Jan 29, 2025
Maintains: Overweight
Price Target: $31 → $30
Current: $12.73
Upside: +135.66%
IGM Biosciences
Jan 13, 2025
Upgrades: Neutral
Price Target: n/a
Current: $1.36
Upside: -
Vir Biotechnology
Jan 9, 2025
Maintains: Neutral
Price Target: $10 → $14
Current: $5.41
Upside: +158.78%
Dec 3, 2024
Maintains: Overweight
Price Target: $63 → $71
Current: $37.87
Upside: +87.48%
Nov 25, 2024
Maintains: Overweight
Price Target: $30 → $43
Current: $36.72
Upside: +17.10%
Nov 19, 2024
Initiates: Overweight
Price Target: $38
Current: $11.37
Upside: +234.21%
Nov 5, 2024
Initiates: Overweight
Price Target: $23
Current: $1.43
Upside: +1,508.39%
Oct 17, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $6.95
Upside: +144.60%
Sep 10, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $3.63
Upside: +478.51%
Aug 7, 2024
Maintains: Overweight
Price Target: $45 → $48
Current: $20.01
Upside: +139.88%
Aug 6, 2024
Maintains: Underweight
Price Target: $11 → $10
Current: $7.89
Upside: +26.74%
Jul 8, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.06
Upside: -
May 3, 2024
Maintains: Neutral
Price Target: $14 → $15
Current: $1.66
Upside: +803.61%
Jan 29, 2024
Upgrades: Neutral
Price Target: $6
Current: $1.48
Upside: +305.41%
Nov 13, 2023
Maintains: Neutral
Price Target: $11 → $10
Current: $5.27
Upside: +89.75%
Oct 19, 2023
Maintains: Overweight
Price Target: $31 → $11
Current: $4.87
Upside: +125.87%
Oct 11, 2023
Maintains: Overweight
Price Target: $62 → $41
Current: $51.77
Upside: -20.80%
Aug 28, 2023
Downgrades: Neutral
Price Target: $300 → $100
Current: $9.69
Upside: +931.99%
Aug 28, 2023
Downgrades: Neutral
Price Target: $28 → $5
Current: $0.56
Upside: +800.74%
Aug 10, 2023
Downgrades: Underweight
Price Target: n/a
Current: $3.74
Upside: -
Aug 9, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $4.32
Upside: +154.63%
Nov 29, 2022
Downgrades: Underweight
Price Target: n/a
Current: $8.36
Upside: -
Feb 9, 2022
Upgrades: Neutral
Price Target: $120
Current: $4.39
Upside: +2,633.49%
Jan 7, 2022
Downgrades: Neutral
Price Target: $750 → $300
Current: $7.84
Upside: +3,726.53%
Oct 8, 2021
Downgrades: Underweight
Price Target: n/a
Current: $3.20
Upside: -
Jul 12, 2021
Initiates: Neutral
Price Target: $50
Current: $11.28
Upside: +343.26%
Jan 29, 2021
Downgrades: Neutral
Price Target: $24 → $9
Current: $2.37
Upside: +279.75%
Jan 29, 2021
Downgrades: Underweight
Price Target: n/a
Current: $3.62
Upside: -
Feb 24, 2020
Initiates: Overweight
Price Target: $42
Current: $2.58
Upside: +1,527.91%
Jan 24, 2019
Upgrades: Neutral
Price Target: $11 → $13
Current: $0.77
Upside: +1,597.13%
Nov 14, 2018
Maintains: Neutral
Price Target: $35 → $11
Current: $0.53
Upside: +1,987.68%